Presumably, next year we’ll get some data from the BLAZE and BEXAR studies. If both or BLAZE show preliminary indications of efficacy and safety, you’d think that one or more parties could become seriously interested in partnering—after all, the PD-1 field with its indications is quite vast compared to MDS or soft tissue sarcomas.
5 Likes